QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today received U.S. marketing (PMA) approval of its therascreen® EGFR RGQ PCR Kit (therascreen EGFR test) as a companion diagnostic to guide the use of AstraZeneca’s IRESSA® (gefitinib) in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). QIAGEN’s therascreen EGFR test was approved by the Food and Drug Administration to enable doctors to identify NSCLC patients who have tumors that are positive for epidermal growth factor receptor (EGFR) mutations and therefore are eligible for treatment with AstraZeneca’s drug.
Archives for July 2015
DNAnexus and Intel to Deploy High-Performance Next-Gen Sequencing Analysis Software for Precision Medicine Research in the Cloud
DNAnexus, the global leader in genome informatics and data management, today announced that it has worked with Intel Corporation, the world’s largest semiconductor company, to deploy elPrep, a high-performance software tool for the preparation of genomic data for large-scale sequence analysis. The first use is by Janssen Research & Development, a division of Janssen Pharmaceutica, which is currently using elPrep in the settings of precision medicine research and clinical applications. It is the mission of Janssen R&D to discover and develop innovative medicines that ease patient’s suffering, and solve the most important unmet medical needs of our time.
Sanguine Brings Smart Technology and Mobile Health Force to the Clinical Trial Space
Sanguine, a leading technology company providing services to the personalized medicine and biomedical research market, recently announced that they will be expanding their services to improve clinical trial efficiency through enhanced patient recruitment, retention and trial procedures. Sanguine, which primarily operated in the pre-clinical space until now, will be fulfilling a big need in later stage clinical development through a combination of their smart technology and adaptable mobile health force.
QIAGEN expands QIAsymphony Test Menu in Partnership with Seegene
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced a collaboration in which Seegene Inc. (096530.KQ) will develop a menu of multiplex assay panels for its modular QIAsymphony RGQ MDx automation platform.